Autopsy report · NCT02346643

A Post Market Evaluation of Chronic intractaBle paIN and the Efficacy of drG stimulatiOn in the Nordic Region

“Budget Allocation Decision by Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 9 months after it had already started.
• Ran for about 2 years 8 months before it stopped.
• 41 participants enrolled.
• Results were posted on the registry 2 years 2 months after it ended.

Vital statistics

Status

Terminated

Sponsor

Abbott Medical Devices

Sponsor type

Industry

Conditions

Chronic Pain

Interventions

Implantation with the commercially available Axium Neurostimulator

Participants

41

Sites

2

Countries

Sweden

Trials that died the same way

• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
  “Sponsor resource allocation” (80% match in meaning)
• Single Ascending Dose Trial in Patients With Type 2 Diabetes
  “Decision by Sponsor” (79% match in meaning)
• A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
  “Sponsor decision - funding issues” (79% match in meaning)
• Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer
  “Sponsor Decision” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.